Canada markets closed

Sutro Biopharma, Inc. (S09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
4.1000-0.1400 (-3.30%)
At close: 03:29PM CET
Full screen
Previous Close4.2400
Open4.0800
Bid4.1000 x 0
Ask4.2600 x 0
Day's Range4.0800 - 4.1000
52 Week Range1.9100 - 5.3500
Volume2,150
Avg. Volume34
Market Cap253.504M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Sutro Biopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences. Conference Details: Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDate: February 13-14, 2024Location: Virtual TD Cowen 44th Annual Health

  • GlobeNewswire

    Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

    Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression Promising clinical activity and tolerability of luvelta as both a monotherapy and in combination across multiple cancers may provide for a significant commercial opportunity Investor webcast today at 1:30 p.m. PT / 4:30 p.m. ET S

  • GlobeNewswire

    Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

    SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor